GlobalData on MSN
Tandem secures FDA approval for Control-IQ+ use in pregnancy
The approval is based on findings from the CIRCUIT trial published in JAMA in October 2025.
US FDA clears Tandem Diabetes Care’s Control-IQ+AID technology for use in pregnancy complicated type 1 diabetes mellitus: San Diego Wednesday, April 29, 2026, 16:00 Hrs [IST] Ta ...
FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type ...
The FDA has approved the Control-IQ+ automated insulin delivery system for use in pregnant women with type 1 diabetes, ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
A new study evaluated the effect of hybrid-closed loop Control-IQ technology in the pooled data from three randomized controlled trials, comparing Control-IQ to a control group using continuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results